United Therapeutics' esuberaprost fails Phase III in PAH

United Therapeutics discontinued development of esuberaprost after the compound failed to meet

Read the full 126 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE